Last Updated: June 24, 2026

Drugs in ATC Class C07


✉ Email this page to a colleague

« Back to Dashboard


Subclasses in ATC: C07 - BETA BLOCKING AGENTS

Market Dynamics and Patent Landscape for ATC Class C07 Beta Blocking Agents

Last updated: June 4, 2026

Beta blocking agents (ATC C07) are a mature, largely generic class with limited patent-led innovation windows outside a small set of branded, long-acting, fixed-dose, and device-adjacent products. The competitive outcome is driven by (1) formulation-dependent patent coverage for extended-release and solubilized actives, (2) method-of-use and combination patents in hypertension and cardiovascular indications, and (3) geographic regulatory and exclusivity differences that gate generic entry. Patent estates for most blockbuster-era betablockers have expired or are near expiry, shifting leverage from primary composition-of-matter to secondary Orange Book listings (formulations, methods, and patents on dosing regimens).

Core market dynamic: pricing pressure and low marginal differentiation dominate. Where patent “thickness” remains, it is concentrated in long-acting and specific delivery technologies (controlled release, once-daily profiles, polymer matrices) and in certain combination products (with diuretics or other cardiovascular classes). For business planning, the practical question is not “is there a beta blocker patent,” but “which specific product strength/formulation and which jurisdiction still has enforceable, FDA-listed exclusivities or unexpired patents.”


What patents protect beta blocking agents (ATC C07) in the US and Europe?

The beta blocker patent landscape is dominated by secondary patents once the earliest compound patents roll off. Coverage typically clusters into:

  • Formulation and dosage form patents: extended-release (ER), controlled release (CR), enteric coatings, osmotic pumps, matrix systems, and fixed-dose combinations.
  • Method-of-use patents: dosing regimens, titration schedules, or specific therapeutic uses such as heart failure phenotypes, angina variants, migraine prophylaxis subsets, or post-MI management.
  • Combination product patents: co-administration and specific ratios with diuretics or calcium channel blockers.
  • Manufacturing process patents: granulation, milling particle size targets, impurity specifications, and scaling changes that preserve stability and bioavailability.

Which beta blockers are most often covered by formulation and method-of-use patents?

In practice, enforceable “late-life” listings concentrate around:

  • Long-acting/once-daily formulations (ER tablets/capsules; controlled release matrices).
  • Specific solubility and bioavailability technologies that support ER exposure profiles.
  • Combination products that remain branded longest due to fixed-dose convenience and payer preferences.

How many patent families typically cover a single marketed beta blocker product?

For still-branded or recently branded assets in C07, the estate often contains:

  • 1 primary composition family (often already expired)
  • 2 to 8 secondary families tied to dosage form, coatings, and stability
  • 1 to 3 families covering methods of use or combination-specific claims
    The count varies by molecule age and whether the product is a reformulation or a fixed-dose combination built later.

When does patent protection expire for beta blockers like metoprolol, bisoprolol, carvedilol, and propranolol?

For most legacy beta blockers, the primary composition-of-matter patents are expired or close to expiry. The gating factors for generic entry shift to:

  1. FDA-listed Orange Book patents (formulation, method-of-use, combination).
  2. Data exclusivity where applicable (newer NDA approvals vs older NDAs).
  3. Patent-term adjustments and extensions that move listed expiration dates.

Typical expiration pattern across the C07 class

  • Primary compound patents: largely expired across major markets.
  • ER/formulation patents: often expire later than the original compound filing date, particularly where reformulations received distinct patentable claims.
  • Last-movers: combination products and reformulated ER products tend to keep patent lists active longer.

Featured snippet answer

Most branded beta blockers in C07 have no remaining broad composition-of-matter protection; the remaining time-to-entry is determined by late-life formulation/method Orange Book patents tied to specific strengths and release characteristics.


What is the Orange Book status of beta blocker products, and how does it differ by formulation strength?

Orange Book protection is product-specific by active ingredient, dosage form, and strength. For C07, this matters because:

  • One strength can be covered by an ER formulation patent while another strength (IR) is not.
  • Combination products can have separate listings even when the component actives are old.

Practical implications for generics

  • A Paragraph IV certification can target a subset of listed patents for a specific strength.
  • Generic launch risk depends on whether the manufacturer plans to file for the same route (oral), same ER profile, and the same excipient system.

Regulatory gating

Even when patents on the active ingredient expire, FDA can still require a certification against remaining listed patents for the approved drug product.


How do Paragraph IV challenges and FDA litigation risk affect beta blocker generic launch timing?

Patent enforcement in C07 is less about “new chemistry” and more about claim scope around:

  • ER release mechanisms
  • bioequivalence exposure matching
  • process-related impurity and stability profiles
  • combination ratio claims

What claims drive Paragraph IV litigation most often?

  • Controlled release and polymer matrix claims
  • Coating and dissolution profile claims
  • Method-of-use dosing regimen claims
  • Combination co-formulation claims

Typical litigation dynamic

Settlements in C07 often produce:

  • delayed launch dates aligned to the last-to-expire patent
  • narrow product carve-outs (strength-specific or dosage-form-specific)
  • potential “design-around” paths that maintain market differentiation

Featured snippet answer

In ATC C07, Paragraph IV risk is concentrated in formulation and dosage-form patents. If a generic can design around dissolution or release profile claims while maintaining bioequivalence, it reduces litigation exposure.


Which companies are challenging beta blocker patents most actively?

Enforcement and challenges are driven by:

  • generic challengers targeting Orange Book patents for specific strengths of ER and combination products
  • branded manufacturers defending specific dose forms where patents remain listed

The competitive map in C07 is typically crowded with multiple ANDA filers and multiple settlements, particularly around:

  • ER once-daily products
  • combo tablets/capsules

Business view

The highest licensing and settlement intensity is seen where:

  • the branded asset still holds meaningful volume
  • a single listed late-life patent controls the generic carve-out for multiple strengths

How do biosimilars and biologic risk apply to ATC C07 beta blockers?

Biosimilar risk is generally not a primary factor for ATC C07 because beta blockers in standard classification are small-molecule drugs. The biosimilar framework is mainly relevant in ATC programs with biologics, which is not the dominant structure for C07.

Featured snippet answer: Biosimilar risk is not a material driver in ATC C07 beta blocking agents. The competition is predominantly ANDA-based generics versus branded small molecules.


What formulations are protected by beta blocker patents (ER, IR, fixed-dose combinations)?

Formulation protection is the main live lever.

ER vs IR: where patents cluster

  • ER tablets/capsules: controlled dissolution, polymer matrices, or osmotic release architectures.
  • IR tablets: fewer late-life formulation patents in many products, but some stability and particle-size claims persist.

Combination products: where patents cluster

  • Fixed-dose combinations with diuretics and/or other cardiovascular drug classes.
  • Patents on ratios, co-grinding, co-processing, and release sequencing.

Manufacturing details that appear in claims

  • particle size distributions and milling processes to manage dissolution
  • excipient selection and amounts for consistent release
  • impurity control and stability targets that support regulatory approval and bioavailability consistency

How strong is the patent estate for beta blockers in 2026, and what does “strength” mean practically?

“Strength” in C07 is measured by enforceability and controllability:

  • Enforceable, FDA-listed claims that correspond to the exact marketed dosage form/strength
  • Recent reformulation patents with clearly defined release profiles
  • Remaining term after accounting for filings and patent-term adjustments
  • Settlement history, which signals whether courts or parties treat the claims as credible barriers

Practical scoring model for investors and licensors

  • Live Orange Book listings count: more listings increase the probability at least one patent blocks entry.
  • Claim breadth: narrow formulation claims are harder to invalidate but easier to design around.
  • Strength of infringement nexus: claim scope tied to specific dissolution targets increases infringement likelihood for close generics.

How does ATC C07 beta blocker market performance drive patent litigation and licensing strategies?

Market dynamics determine whether disputes are worth prosecuting:

  • High volume, low differentiation makes settlements and design-arounds rational.
  • Payer preference for once-daily regimens keeps ER products economically important, even late in life.
  • Direct-to-pharmacy substitution increases the value of delayed launch windows for branded firms and aligns litigation with last-to-expire patents.

Licensing strategy patterns

  • Branded firms license if they need to preserve downstream supply and reduce litigation cost.
  • Generic firms seek licensing to avoid injunction risk and preserve launch readiness.

Which beta blockers have the highest revenue exposure from generic entry?

Revenue exposure typically concentrates in:

  • branded ER once-daily formulations where late-life formulation patents persist
  • fixed-dose combinations where “product identity” is tied to the marketed tablet/capsule structure

Across C07, IR-only products often see faster generic normalization, while ER and combination products experience longer defense and delayed generic penetration.


How does the patent landscape for beta blockers compare with other ATC cardiovascular classes (e.g., C08 calcium channel blockers)?

C07 differs from some other cardiovascular classes by:

  • broader legacy generic availability for many active ingredients
  • a greater reliance on formulation-level and product-level patents in remaining branded pockets
  • less biological complexity and fewer biosimilar frameworks

As a result, generic entry risk is more “engineering and formulation” driven than “biologic interchangeability” driven.


What manufacturing/IP barriers slow down generic beta blocker launches?

Even with patent clearance, generic launches can be slowed by:

  • development of ER dissolution profiles that match the reference product
  • impurity control and stability demonstration tied to release characteristics
  • scale-up reproducibility for controlled release polymers or coatings
  • bridging studies for switching release mechanisms while maintaining bioequivalence

These barriers often determine whether “design-around” patents can be avoided without triggering new regulatory delays.


What generic entry risks exist for beta blockers after the last listed Orange Book patent expires?

Last-patent expiry does not automatically create immediate generic entry. Risks include:

  • whether remaining patents exist but are not listed for the intended strength
  • whether patents are tied to specific manufacturing methods, which can still be asserted indirectly
  • whether product improvements created new ANDAs under distinct product codes

For business planning, the generic window usually opens fastest when:

  • multiple listed patents expire on similar dates
  • the dosage form is standard and easy to replicate
  • settlement agreements do not impose launch carve-outs

Key Takeaways

  • ATC C07 beta blocking agents are predominantly mature, with remaining leverage concentrated in formulation and dosage-form patents, not broad composition-of-matter.
  • Generic entry timing is mainly dictated by FDA-listed Orange Book patents tied to specific strengths and release profiles, especially ER and fixed-dose combinations.
  • Paragraph IV risk is highest when patent claims map tightly to ER dissolution/release characteristics and to the exact marketed product identity.
  • “Patent strength” in C07 is operational: the presence of live Orange Book listings and enforceable, dosage-form-specific claim scope.

FAQs

  1. What drives the latest patent expirations for beta blocker products in ATC C07?
    Late-life formulation and dosage-form patents for ER release characteristics and specific combination tablet/capsule designs.

  2. Are bioequivalence and formulation design-around the main barriers to generic beta blocker entry?
    Yes. In C07, the practical barriers are engineering the ER/IR profile and meeting stability and impurity targets while maintaining bioequivalence.

  3. Do patent carve-outs typically occur by strength or by dosage form for beta blockers?
    Yes. Settlements and certifications often carve out by marketed strength and ER/IR product identity.

  4. What types of claims most often survive into the late life of beta blocker products?
    Polymer matrix, coating/dissolution profile, controlled release mechanism, and method-of-use dosing regimen claims.

  5. How should licensing strategy differ for ER once-daily beta blockers versus IR formulations?
    ER once-daily products typically justify more aggressive patent-specific licensing and design-around planning because formulation patents are more likely to remain live and directly map to product identity.


References

  1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
  2. U.S. Patent and Trademark Office. Patent Term Adjustment and Related Patent Term Provisions. USPTO.
  3. FDA. Guidance for Industry: Preparation of Voluntary Scientific and Technical Information Related to Patents and Related Enforcement. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.